SecBot SecBot

VOR

Vor Biopharma Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001817229 Biotech & Drug Discovery
$18.97 −0.45 (−2.32%)
Nov 16 4:00 PM ET · prev $19.42
Market cap
$1.2B
Small cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
$40.00
+111% · range $27.00–50.00
1 year
+89.3%
from $10.02 · Nov 17
30 days
+5.2%
from $18.04
52-week range
$6.86–25.10
−24% from high · low Nov 20
Avg volume 20D
719.1K
shares / day
Short interest
7.50M
≈12.2% of shares · +0.8%
Days to cover
9.9
at average volume
Insider net
−$49.4M
0 buyers · 1 seller · 12 mo
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $49.4M.

  • InstitutionsBULLISH

    Q3 2026: 23 added (2 new), 4 trimmed or exited. Largest new: Federated Hermes, $14.5M.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.933 → −$0.841 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.8% to 7.50M shares. 9.9 days to cover, ≈12.2% of shares.

  • TrendRANGE

    5% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$14.5M
in new stakes · top 1 shown
FundMoveSharesValue
FMR LLCADD6,759,007$129.0M
FEDERATED HERMES, INC.NEW760,221$14.5M
MARSHALL WACE, LLPDOUBLED560,715$10.7M
AXIOM INVESTORS LLC /DEADD124,196$2.4M
MORGAN STANLEYADD101,018$1.9M
ALPS ADVISORS INCADD78,371$1.5M
JPMORGAN CHASE & COADD34,397$630.5K
BNP PARIBAS FINANCIAL MARKETSDOUBLED31,311$597.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy6Buy6Hold2Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +111%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026William Blair
INITIATE
INITIATEOutperform
Aug 12, 2026Wedbush
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$49.4M
sold · 1 insider
DateInsiderTypeValue
Nov 2, 2026
Sokolove Jeremy Brett
Chief Medical Officer
Nov 2, 2026
TAX W/H$36.9K
Oct 2, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Oct 2, 2026
EXERCISE$6.4K
Aug 24, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Aug 24, 2026
EXERCISE$5.6K
Jul 16, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Jul 16, 2026
EXERCISE$4.2K
Jul 16, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Jul 16, 2026
EXERCISE$10.5M
Jul 16, 2026
RA CAPITAL MANAGEMENT, L.P.
10%+ Owner
Jul 16, 2026
SELL$4.2K
Jul 7, 2026
ZACCARDELLI DAVID
Director
Jul 7, 2026
AWARD42,658 sh
Jun 11, 2026
Levin Andrew David
Director
Jun 11, 2026
AWARD57,162 sh

Earnings setup

Estimates
−$0.84
EPS estimate, this quarter
+10%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.84-$0.95–-$0.64+11.7%$0.00
Next Q-$0.99-$0.99–-$0.99No data$0.00
Current FY-$6.67-$8.64–-$3.40-2.2%$0.00
Next FY-$3.34-$3.90–-$2.53+12.3%$0.00

Short side

FINRA· Oct 30, 2026
7,504,425
shares short
+0.8%
vs prior settlement
9.9
days to cover
≈12.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Vor Biopharma expanded its license agreement with RemeGen to include RC298, a next-generation dual BAFF/APRIL…
8-K · Impact 5/10
Nov 5, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 6,318,525 shares of Vor Biopharma…
SC 13G/A · Impact 2/10
Nov 4, 2026 Other
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnolo
Nov 2, 2026 Insider
Sokolove Jeremy Brett surrendered for taxes 1,917 shares
Chief Medical Officer @ $19.25 ($36.9K)
Oct 22, 2026 Press
Vor Bio announced final two-year Phase 3 TELIGAN results for telitacicept in IgA nephropathy, showing a statistically…
Impact 7/10
Oct 5, 2026 Press
Vor Bio granted stock options and RSUs to 9 newly hired employees as inducement awards under Nasdaq Rule 5635(c)(4)…
Impact 2/10
Oct 2, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. acquired via exercise 500 shares
10%+ Owner @ $12.80 ($6.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

11 filings · 6 press releases · 0 bullish · 1 bearish · 10 neutral
All VOR filing & press-release reports (17)